Inhibitors of EZH2
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.
13 Citations
15 Claims
- 1. A compound which is
-
4. A pharmaceutical composition comprising 5-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-{(1R)-1-[trans-4-(3-methoxyazetidin-1-yl)cyclohexyl]ethyl}-3-methyl-5,6,7,8-tetrahydro-4H-thieno[3,2-c]azepin-4-one or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, carriers, or diluents.
- 5. A method of treating cancer in a patient, wherein the cancer is selected from the group consisting of lymphomas, rhabdoid tumors, tumors which lack or are defective in one or more components of the SWI/SNF complex, MLL complexes, and constitutively active PI3K pathway, sarcomas, multiple myeloma, melanoma, gastrointestinal cancer, colorectal cancer, lung cancer, kidney cancer, breast cancer, ovarian cancer, and prostate cancer comprising administering to the patient, an effective amount of 5-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-{(1R)-1-[trans-4-(3-methoxyazetidin-1-yl)cyclohexyl]ethyl}-3-methyl-5,6,7,8-tetrahydro-4H-thieno[3,2-c]azepin-4-one or a pharmaceutically acceptable salt thereof.
Specification